National Vision Holdings Earnings Call Transcripts
Fiscal Year 2026
-
Guidance was reiterated with comp and margin growth, and $20M in share buybacks completed. Technology upgrades and a premium product shift are driving higher-value customer engagement, while store growth will re-accelerate after 2028. Significant management and cultural changes support margin expansion and cost savings.
-
Q1 2026 saw 6.6% revenue growth, 210 bps margin expansion, and strong EPS gains, driven by premiumization, digital upgrades, and a shift toward managed care. Guidance for 2026 is reaffirmed, with ongoing investments in product, digital, and store segmentation expected to offset near-term traffic headwinds.
-
Managed care customers now make up 42% of the mix, driving higher average transactions and premium product sales. Eye exam growth outpaces the industry, aided by rebranding and digital investments. Expansion of smart eyewear and remote care, along with cost savings and margin initiatives, position the business for long-term growth.
-
A digital transformation is underway, with early results showing improved profitability and a shift toward premium products and customer segments. Investments in technology, customer experience, and targeted marketing are driving growth, with long-term goals of sustained revenue and margin expansion.
Fiscal Year 2025
-
Delivered strong 2025 results with 9% revenue growth, 56% higher adjusted operating income, and significant margin expansion, driven by a shift to more profitable customer cohorts and premium products. 2026 guidance calls for continued growth, margin improvement, and disciplined capital allocation.
-
Leadership is executing a transformation focused on targeting more profitable customer segments, optimizing costs, and modernizing technology. Margin expansion and high single-digit revenue growth are targeted through segmentation, premium product focus, and disciplined investment, with store growth paused to fund these initiatives.
-
A bold transformation is underway, targeting higher-value customer segments and premium products, supported by data-driven marketing, refreshed brands, and disciplined cost management. High single-digit revenue growth and operating margin expansion are projected, with significant investments in technology, store growth, and customer experience enhancements.
-
Delivered strong Q3 results with 7.9% revenue growth and 7.7% comp sales increase, driven by higher-value customer segments and premium product adoption. Raised full-year guidance, maintained strong liquidity, and continued strategic investments in marketing, technology, and store expansion.
-
The business is modernizing rapidly, shifting focus to managed care and higher-value segments, with new leadership, brand campaigns, and operational upgrades. Margin expansion and cost controls are underway, while doctor recruitment and remote care initiatives strengthen service delivery.
-
Q2 saw record results with 7.7% revenue growth, 5.9% comp sales growth, and a 69% increase in adjusted operating income. Brand modernization, CRM upgrades, and premium product expansion are driving performance, leading to a raised full-year outlook despite macro uncertainty.
-
Leadership transition is underway as the company accelerates its transformation, focusing on premiumizing its assortment, modernizing marketing, and targeting managed care and progressive lens consumers. Q1 2024 showed strong revenue and profit growth, with further cost optimization and expansion planned.
-
Q1 2025 saw strong revenue and comp growth, driven by transformation initiatives and focus on higher-value customer segments. Guidance for the year was raised, with continued momentum expected, while tariff risks are being proactively managed through pricing and cost actions.
-
Transformation focuses on segmentation, digitization, and targeting managed care, progressive, and outside Rx consumers. Investments in technology, pricing, and personalized marketing are driving growth and profitability, while supply chain risk is minimized. New initiatives and partnerships will roll out through the year.
Fiscal Year 2024
-
Fourth quarter and full-year 2024 results showed revenue and margin growth, driven by managed care and pricing actions, with transformation initiatives underway. 2025 guidance reflects continued growth, cost reductions, and investments in technology, but incorporates caution due to recent traffic volatility.
-
Revenue grew 2.9% to $451.5M, led by managed care, while cash-pay and e-commerce remained soft. Store closures and moderated new openings aim to boost profitability, with $4M in EBITDA improvement expected by 2026. Guidance for 2024 is reiterated, with continued focus on operational enhancements.
-
Remote eye exams are expanding and improving efficiency, helping address optometrist shortages. Promotions and new product offerings are driving traffic, especially among value-focused and managed care customers, while store optimization and digitization aim to support margin recovery.
-
Q2 revenue grew 4.6% to $452M, with adjusted EPS up to $0.15 and strong managed care comps, but macro pressures and lower-than-expected improvement led to reduced FY2024 guidance. Store optimization and remote exam expansion continue, with leadership changes and a focus on profitability.
-
The business has adapted to post-COVID disruptions by expanding remote eye exams, improving doctor retention, and selectively raising prices on ancillary products. Efficiency gains and digital innovation are expected to drive future growth, while AI initiatives aim to unlock new healthcare revenue streams.
-
The company is adapting to post-COVID challenges by expanding remote eye exams, digitizing operations, and exiting low-margin Walmart contracts. Margin expansion and normalized growth are expected by late 2025, with AI-driven healthcare services offering long-term upside.